A common polymorphism, rs7566605, 10 kb upstream of the insulin-induced gene 2 transcription start site has been associated with obesity in Caucasian and African-American populations, with the hypothesis that an alteration in gene expression results in elevated plasma triglyceride levels. The goal of this study was to verify the findings in a cohort of 2721 healthy Caucasian men (second Northwick Park Heart Study), and a separate study of 747 type 2 diabetic patients from Caucasian, Afro-Caribbean and Indian groups (University College London Diabetes and Cardiovascular Disease Study).The rs7566605 single-nucleotide polymorphism (SNP) was not related to plasma triglyceride levels in either study, and we found no association with body mass index or obesity in either cohort, despite having the power to detect the previously reported effect. This suggests that, at the least, the true size of the effect on obesity of this SNP is likely to be considerably less than reported previously.
A recent whole-genome study identified a common genetic variant, 10 kb upstream of the INSIG2 (insulin-induced gene 2) gene (rs7566605) that was associated with obesity in several cohorts. 1 It was postulated that this variant itself, or another in strong linkage disequilibrium (LD), alters the level of expression of INSIG2, leading to modified inhibition of fatty acid and cholesterol synthesis. To verify these findings, we genotyped two UK-based cohorts for rs7566605: NPHSII (second Northwick Park Heart Study), and UDACS (University College London Diabetes and Cardiovascular Disease Study). The details of NPHSII are described elsewhere. 2 Briefly, the study consists of 3012 unrelated Caucasian males with a mean (s.d.) age of 56.1 (3.5) years, recruited from nine general practices in the UK, and followed prospectively for a median of 13.7 years. Exclusion criteria at baseline were a history of myocardial infarction, cerebrovascular disease, life-threatening malignancy or regular medication with aspirin or anticoagulants. All men gave written informed consent. UDACS is a cross-sectional sample of individuals with type 2 diabetes (T2D) according to the World Health Organization criteria, 3 designed to study the association between common variants in inflammatory/metabolic genes and biochemical risk factors implicated in coronary heart disease (CHD) in patients with diabetes. The sample is detailed elsewhere. 4, 5 Ethical approval was obtained for this study from the UCLH Ethics Committee. The subjects in NPHSII, who developed T2D during follow-up were identified as described. 6 Genotyping of rs7566605 single-nucleotide polymorphism (SNP) was carried out using the TaqMan Assay-by-Design platform (Applied Biosciences, ABI, Warrington UK). Reactions were performed on 384-well microplates and analysed using ABI TaqMan 7900HT software (probe details available on request). Statistical analysis was performed with Stata (Version 8, StataCorp, TX, USA). Mean values were compared by analysis of variance and percentages by w 2 or Fisher's exact test. Where results from different ethnic groups were combined, adjustment was made using regression estimates of the effects. Table 1 presents the levels of three relevant traits by genotype for NPHSII and UDACS. There were no statistical differences in body mass index (BMI), obesity or triglyceride levels between genotypes. Using the recessive model proposed by Herbert et al., the GG/CG genotypes were combined and analysed against the CC genotype. The previous study identified an association between obesity (BMI430 kg/m 2 ) and the CC genotype. In both the Caucasian UDACS and NPHSII cohorts, there was no significant difference in these two groups for obesity status and genotype (P ¼ 0.39 and 0.54, respectively). Similarly, there was no association between both BMI and body fat measurements and genotype in NPHSII (data not shown).
The UDACS cohort comprised T2D patients from Caucasian (n ¼ 572), Indian (n ¼ 105) and Afro-Caribbean (n ¼ 70) backgrounds. It is of note that the C-allele frequency was not statistically different between these three ethnic groups (Caucasian: 0.334 (95% confidence interval (CI): 0.307-0.362); Indian: 0.364 (CI: 0.301-0.436); Afro-Caribbean: 0.286 (CI: 0.213-0.368) P ¼ 0.29). The study by Herbert et al. examined an African-American cohort (Maywood), identifying an odds ratio of 1.22 (P ¼ 0.008) for obesity. Our study, albeit smaller, failed to replicate this association. Furthermore, there was no association between genotype and obesity/BMI within the Indian subgroup of UDACS (Table 2) . Although it is possible that a genotype effect on obesity may have been masked by the drug therapies being used to treat diabetes or dietary and lifestyle advice being given, we believe this is unlikely. There were no significant differences in duration of diabetes, prevalence of CHD or use of medication by genotype (all P40.3 data not shown). The frequency of the rs7566605 genotypes in the UDACS T2D Caucasian patients was not significantly different from that in the healthy NPHSII Caucasian subjects, indicating no susceptibility toward developing T2D (comparison of allele frequency, P ¼ 0.14).
The two cohorts examined in this study had sufficient power to detect the reported association with obesity and BMI: NPHSII had 90% power to detect a 0.7 BMI unit difference, and UDACS a 1.7 BMI unit difference at the 5% significance level. This was not observed in either case. The authors hypothesize that alteration of INGIS2 activity may lead to obesity by the raising of plasma triglyceride levels and subsequent storage in adipose tissue. In this study, there was no relationship between INSIG2 genotype and triglyceride levels, suggesting that their observed association, if true, may be due to a different mechanism. Herbert et al. reported a lack of association between rs7566605 and obesity in the Nurses Health Study (n ¼ 2726), postulating that this may be due to the fact that there were few individuals with a high BMI in this study, or owing to differences in environment INSIG2 gene polymorphism not associated with obesity AJP Smith et al and lifestyle. In NPHS2 and UDACS, the mean BMI is similar to that reported in both the Framingham and KORA studies making this explanation unlikely for the lack of association seen here. Our study casts further doubt on the association; we cannot rule out a genuine association, but our data would indicate that the magnitude of the effect of obesity is significantly less than reported previously. Our failure to replicate the association between the CC genotype of rs7566605 and obesity in two large studies highlights the importance of independent studies in verifying genetic associations; further studies by additional groups, and the subsequent use of meta-analysis may help to quantify the true level of association. It is also possible that the use of additional SNPs at the INSIG2 gene locus would shed further light on the impact of variation in this gene on measures of adiposity and plasma lipid levels. For complex traits, no single SNP, even if it is itself functional, would detect all the common variation at a particular locus, and although as reported, 1 there do not appear to be non-synonymous SNPs in INSIG2, it is unlikely that rs7566605, located 10 kb upstream at the transcriptional start site of the gene, is itself functional, but is rather a marker for functional variation elsewhere in the gene (or an other gene at the locus). Genotyping using several SNPs may therefore be more fruitful and give more consistent results. 7 It is also possible that interaction between INSIG2 variants and environmental factors such as diet may be influencing the development of obesity and explain the differences seen between the results here in UK subjects and in the original paper, which examined subjects living in the US. 8 Finally, although the study here of individuals of African origin failed to confirm the associations in African-Americans reported, 1 this could be explained by different LD between the SNP used and the functional site in individuals of different ethnic origin, with genetic background altering the SNP phenotype association through epistasis. 
